<DOC>
	<DOCNO>NCT00478725</DOCNO>
	<brief_summary>To study absorption , distribution , metabolism excretion GW786034 , absorption single IV dose GW786034</brief_summary>
	<brief_title>Part A : Radiolabel Study With GW786034 Part B : Single Dose GW786034</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion criterion : Subject must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment followup . Procedures conduct part subject 's routine clinical management ( e.g. , blood count , image study ) obtain prior signing inform consent may utilize screen baseline purpose provide procedure conduct specify protocol . Has histologically cytologically confirm advanced solid tumor malignancy . For Part A : Males , age : 30 year great . For Part B : Males Females , age : 18 year great . For Part A B , males meet follow criterion . A male subject female partner childbearing potential eligible enter participate study : Agrees use doublebarrier contraception ( condom spermicidal jelly , foam , suppository film , condom partner use diaphragm spermicide ) , OR Agrees complete abstinence sexual intercourse 14 day exposure investigational product , clinical trial , least 21 day last dose investigational product . For Part B , females meet follow criterion : A female subject eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : A hysterectomy A bilateral oophorectomy ( ovariectomy ) A bilateral tubal ligation Is postmenopausal ( total cessation menses &gt; / 1 year ) , OR Childbearing potential negative serum pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible , agree use adequate contraception . GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device ( IUD ) document failure rate le 1 % per year . Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigational product , clinical trial , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . Note : Oral contraceptive consider reliable due potential drugdrug interaction . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Body weight &gt; / 50 kg . Adequate organ system function define Table 1 . Ability swallow retain oral medication . Exclusion criterion : History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previously treat CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior begin study treatment . Screening CNS image study ( CT scan MRI ) require clinically indicated subject history CNS metastases . Clinically significant gastrointestinal ( GI ) abnormalities include , limited : malabsorption syndrome , history resection stomach small bowel , active peptic ulcer disease , inflammatory bowel disease , ulcerative colitis condition increase risk perforation , history abdominal fistula , GI perforation intraabdominal abscess within 4 week prior begin study treatment . Presence uncontrolled infection . Corrected QT interval ( QTc ) &gt; 480 msec . History one follow cardiovascular condition within past 6 month : congestive heart failure , cardiac angioplasty stenting , myocardial infarction , unstable angina OR symptomatic peripheral vascular disease . Has poorly control hypertension ( systolic blood pressure [ SBP ] &gt; / 140 mmHg , diastolic blood pressure [ DBP ] &gt; / 90 mmHg ) . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . The blood pressure ( BP ) must reassess 2 occasion separate minimum 24 hour . The mean SBP/DBP value BP assessment must &lt; 140/90 mmHg order subject eligible study . History cerebrovascular accident pulmonary embolism within past 6 month . History untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . Prior major surgery trauma within past 28 day presence wound , fracture ulcer fully heal . Evidence active bleeding , bleed diathesis hemoptysis within 6 week prior study treatment . Use prohibit medication within timeframes specify Section 9.2 , Prohibited Medications protocol . Use investigational agent , include investigational anticancer agent within 28 day 5 halflives , whichever longer , precede first dose pazopanib . Treatment cancer therapy ( include chemotherapy , radiation therapy , immunotherapy , biologic therapy , hormonal therapy , surgery tumor embolization ) within 14 day prior first dose pazopanib . Note : Current treatment leuprolide permit . Any ongoing potentially reversible toxicity prior anticancer therapy &gt; Grade 1 toxicity prior anticancer therapy progress severity . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , obtain informed consent compliance study , include condition could interfere accurate assessment recovery [ 14C ] . History presence hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Advanced Cancer</keyword>
</DOC>